News on screening, diagnosis and treatment of prostatic cancer;Actualités sur le dépistage, le diagnostic et le traitement des cancers de prostate

Bulletin du Cancer

Volumn 89, Issue 1, 2002, Pages 37-45

  Chauvet, Bruno ^a   Villers, Arnauld ^a   Davin, Jean Louis ^a   Nahon, Sophie ^a  

^a INSTITUT SAINTE CATHERINE   (France)

Author keywords

Brachytherapy; Chemotherapy; External beam radiotherapy; Hormonotherapy; Prostatectomy; Prostatic carcinoma; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; HUMAN; MALE; PRACTICE GUIDELINE; PROSTATE CARCINOMA; PROSTATECTOMY; SCORING SYSTEM; TREATMENT INDICATION;

ANDROGEN ANTAGONISTS; HUMANS; LYMPHATIC METASTASIS; MALE; MASS SCREENING; PALPATION; PATIENT EDUCATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 0036175053     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Participation française à l'étude européenne de dépistage randomisé du cancer de la prostate par le dosage sérique du PSA: Étude de faisabilité concernant 2 650 hommes représentant 10 % de l'effectif total de 26 500 hommes de 55 à 69 ans de la population du tarn
2. Screening for prostate cancer: Evidence and perspectives
3. Le dépistage ciblé du cancer de la prostate dans les familles à risque augmente significativement la détection de l'affection chez les parents du premier degré
4. Defining and updating the American Cancer Society guideline for the cancer-related check-up: Prostate and endometrial cancer
5. AMA report 9 of the council on scientific affairs. Screening and early detection of prostate cancer
6. Clinical guidelines. Part III: Screening for prostate cancer
7. Recommendations on screening in the European Union
8. Conclusions sur le dépistage du cancer de prostate
9. Hereditary prostate cancer and other genetic predispositions to prostate cancer
10. PSA libre: L'utilisation en routine est prématurée pour le dépistage du cancer de prostate
11. Biopsies prostatiques: Modalités techniques et conditions de l'examen
12. Reliability of CT for determining lymphatic involvement in patients with prostate cancer
13. Determining local-regional extension of prostate cancer
14. The clinical value of PSA and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer
15. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level
16. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer
17. Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: An analysis of four statistical models
18. Imaging prostate cancer
19. The role of radiotherapy after radical prostatectomy
20. Pathologic assessment of the surgical specimen
21. Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers
22. Indications and contraindications for nerve-sparing radical prostatectomy
23. Laparoscopie en urologie
24. Prevention and management of erectile dysfunction following radical prostatectomy
25. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
26. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience
27. Local control of prostate cancer with radiotherapy: Frequency and prognostic significance of positive results of post-irradiation prostate biopsy
28. The importance of local control in the treatment of prostatic cancer
29. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement
30. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125 I implantation
31. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose
32. A ten year follow up of 682 patients treated for prostate cancer with radiation therapy in the United States
33. Comparison of radiation side-effects of conformal radiotherapy in prostate cancer: A randomised trial
34. Acute toxicity in pelvic radiotherapy: A randomised trial of conformal versus conventional treatment
35. Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment
36. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate
37. External beam radiotherapy dose response of prostate cancer
38. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
39. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
40. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
41. Conventional vs conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity
42. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: Results of a self-assessment questionnaire
43. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms
44. Rectal bleeding after conformal 3d treatment of prostate cancer: Time to occurrence, response to treatment and duration of morbidity
45. The National Cancer data base report on increased use of brachytherapy for the treatment of patients with proste carcinoma in the US
46. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer
47. A comprehensive review of prostate cancer brachytherapy: Defining an optimal technique
48. Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up
49. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent Iodine-125 implantation for early-stage prostatic cancer
50. Temporal resolution of urinary morbidity following prostate brachytherapy
51. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7-year biochemical progression analysis
52. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation
53. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2 222 patients: Results from a single practice
54. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
55. Long term results of immediate adjuvant hormonal therapy with goserilin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study
56. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
57. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
58. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials
59. Portal imaging protocol for radical dose-escalated radiotherapy treatment of prostate cancer
60. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation
61. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy
62. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer
63. Is « off protocol » chemotherapy for androgen-independent carcinoma of prostate warranted?
64. Management of hormone refractory prostate cancer: Current standards and future prospects
65. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A canadian randomized trial with palliative end points
66. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer
67. Health related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone
68. Phase II study of estramustine phosphate in advanced hormone refractory prostate cancer with increasing prostate specific antigen levels
69. Vinblastine versus vinblastine plus oral estramustine phosphate in patients with hormone-refractory cancer: A Hoosier Oncology Group and Gox Chase Network Phase III trial
70. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
71. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780
72. Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: A phase II trial of oral estramustine and oral etoposide
73. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer